Masoud Toloue: I’ll give a broad stroke there, Kyle, on sort of the operational efforts and then on that I can comment on some of the margin and cache. So, you know, what we’re doing right now in Q3 and Q4 is really focusing a lot of our resources on upgrades of the product line in preparation for the new assay deployments. We believe, and as you can see in the last several quarters, that these new asset deployments are going to be gross margin accretive. Now, while we’re putting them, into the line in Q3 and Q4, that’s a lot of effort and a lot of focus from the team. But we expect those new product lines, as we’ve been investing in the last six quarters, will be positive for the business. And we’ll be able to get those products to our customers in an efficient way and a lot faster.
So we’re bullish on that aspect of getting this there. And as I said in the very beginning of the prepared remarks, we are out. you know, substantially completed a lot of the heavy lifting and we’re going to be now doing implementation in the last couple of quarters. So that’s that. And then on the guidance for next year, you know, I think just similar to what Vandana said, you know, we’re going to talk about that in February and we’ll have a better sense, but you know, we still have a strong view that our, you know, research business, you know, continues to be strong and that we’re seeing that, you know, continued Samoa demand. Thank you. for sensitivity and for our platforms and solutions.
Vandana Sriram: Yeah, I’d say, you know, very consistent with everything Masoud said. We do expect 2024 to come in with a position of strength and for us to be able to keep building off that. On the cash side, the only other thing that I would add is, as Masoud mentioned in his prepared remarks, the way we think about the business is, we will continue to drive the REO business to more and more efficiency, better performance, working better with our customers. So we’ll continue to focus on that. And we’ll continue to drive it towards getting to cash flow break-even. We’ve previously guided to that 170 to 190 for cash flow break-even, and we’ll continue to work towards that. At the same time, we will deploy some capital into diagnostics. Right now it’s really small and right now it’s really more focused on building out our infrastructure. But you will see us be very focused in where we deploy our capital and making sure that aligns to our strategy.
Kyle Mikson: Okay. That was great. And just one last one. Masood, as we stack up all these options in Alzheimer’s diagnostics, Quanterix clearly has the most sensitive tests. p-tau217 kind of, helped out with specificity, which I think is what will ultimately lead to that kind of rule-in type test for maybe screening. But how do you think about, like, what’s a clinically meaningful sensitivity level for neurology biomarkers? And then on that note, like what type of tests would be best positioned as a monitoring test in AD? Like would the number of markers or the levels of some of these metrics matter for that type of product rather than the one you’ve already announced in Lucent AD?
Masoud Toloue : Yes, great question Kyle. The sensitivity I would expect, you know expect a good test to have a sensitivity of 90% and above. So that’s, I think, a threshold. Greater than 90% accuracy. And to your point, strong specificity if it’s going to be a real end test. So I think that’s important for diagnostic. And then in terms of monitoring, staging, monitoring, first, I believe that a tau marker is in that multiplex for monitoring and staging. But we also are seeing the importance of NFL, GFAP, and a few new types of tau variants that we’ve been doing a lot of work on in our pipeline. So, from a monitoring perspective, I could see it being multi-marker. And then differential diagnosis. Let’s also consider that there are folks coming in to the neurologist office and there are the signs of dementia, but we’re not seeing the amyloid pathology.
Then what? What is that? And there I think the need for differential diagnosis is important. And there you’ll for sure need additional markers beyond tau to be able to provide that differential diagnosis. So we’re working with several partners. We’re in a few clinical trials that are looking at this, including our own, where we’re looking at a broad-based patient set in a multi-marker setting. And I think the point of all of this is, 2017 is great, and it’s, we believe the best marker for the diagnosis, but there’s still a lot of work to do, Kyle, in research, in discovery, additional clinical work and testing for what’s a much larger picture. And if you sort of look and squint at what we’re seeing in the field and what’s coming out from industry publications, it’s going to be a multi-marker test that’s going to require sensitivity for all the markers to be able to tell the whole picture.
Kyle Mikson: Got it. Okay. That’s perfect. Thanks, Masoud. Thanks, guys.
Masoud Toloue : Thanks, Kyle.
Operator: Thank you. This does conclude the question-and-answer session. Thank you for your participation in today’s conference. This concludes our program. You may now disconnect.
